Telix Pharmaceuticals Limited

telixpharma.com

Telix Pharmaceuticals
Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR).

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

TELIX GRANTED FDA ORPHAN DRUG DESIGNATION FOR BONE MARROW CONDITIONING TREATMENT

Telix Pharmaceuticals Limited | March 29, 2022

news image

Telix Pharmaceuticals Limited announces that the United States Food and Drug Administration has granted Orphan Drug Designation for TLX66 for conditioning treatment prior to hematopoietic stem cell transplant. The granting of an ODD for TLX66 qualifies Telix for various drug development incentives, which may include FDA administered market exclusivity for seven years, waived FDA prescription drug user fees, and tax credits for R&D and clinical development costs. Bone marrow co...

Read More

Business Insights

TELIX PHARMACEUTICALS ANNOUNCES LICENCE AGREEMENT WITH LILLY FOR OLARATUMAB

Telix Pharmaceuticals Limited | April 11, 2022

news image

Telix Pharmaceuticals Limited announces that it has entered into a licence agreement with Eli Lilly and Company under which Telix is granted exclusive worldwide rights to develop and commercialise radiolabelled forms of Lilly's olaratumab antibody for the diagnosis and treatment of human cancers. Telix's initial development focus will be on a rare type of cancer known as soft tissue sarcoma. Olaratumab was originally developed by Lilly as a monoclonal antibody targeting Pl...

Read More

Business Insights

ILLUCCIX® AVAILABLE ON HIGH ACTIVITY GALLIUM GENERATOR TECHNOLOGY TO MEET HIGH DEMAND

Telix Pharmaceuticals Limited | November 23, 2022

news image

Telix Pharmaceuticals Limited announces Illuccix® with up to 50mCi for radiolabeling is available for use on 100mCi gallium generators, an important development in radioisotope production. High activity generators from Eckert & Ziegler Strahlen- und Medizintechnik AG increase activity from 50mCi to 100mCi and will be integral to expanding patient access to gallium-based radiopharmaceuticals as demand for PSMA-PET imaging in the United States continues to grow. This technol...

Read More

Business Insights, PRACTICE MANAGEMENT

TELIX ANNOUNCES EXECUTIVE LEADERSHIP APPOINTMENTS

Telix Pharmaceuticals Limited | December 05, 2022

news image

Telix Pharmaceuticals Limited announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession planning. Richard Valeix promoted to Group Chief Commercial Officer Richard Valeix, who has been in the role of Chief Executive Officer of Telix's Europe Middle East and Africa operations since joining Telix in May 2021, has been appointed to the newly created role of Group Chief Com...

Read More
news image

Business Insights

TELIX GRANTED FDA ORPHAN DRUG DESIGNATION FOR BONE MARROW CONDITIONING TREATMENT

Telix Pharmaceuticals Limited | March 29, 2022

Telix Pharmaceuticals Limited announces that the United States Food and Drug Administration has granted Orphan Drug Designation for TLX66 for conditioning treatment prior to hematopoietic stem cell transplant. The granting of an ODD for TLX66 qualifies Telix for various drug development incentives, which may include FDA administered market exclusivity for seven years, waived FDA prescription drug user fees, and tax credits for R&D and clinical development costs. Bone marrow co...

Read More
news image

Business Insights

TELIX PHARMACEUTICALS ANNOUNCES LICENCE AGREEMENT WITH LILLY FOR OLARATUMAB

Telix Pharmaceuticals Limited | April 11, 2022

Telix Pharmaceuticals Limited announces that it has entered into a licence agreement with Eli Lilly and Company under which Telix is granted exclusive worldwide rights to develop and commercialise radiolabelled forms of Lilly's olaratumab antibody for the diagnosis and treatment of human cancers. Telix's initial development focus will be on a rare type of cancer known as soft tissue sarcoma. Olaratumab was originally developed by Lilly as a monoclonal antibody targeting Pl...

Read More
news image

Business Insights

ILLUCCIX® AVAILABLE ON HIGH ACTIVITY GALLIUM GENERATOR TECHNOLOGY TO MEET HIGH DEMAND

Telix Pharmaceuticals Limited | November 23, 2022

Telix Pharmaceuticals Limited announces Illuccix® with up to 50mCi for radiolabeling is available for use on 100mCi gallium generators, an important development in radioisotope production. High activity generators from Eckert & Ziegler Strahlen- und Medizintechnik AG increase activity from 50mCi to 100mCi and will be integral to expanding patient access to gallium-based radiopharmaceuticals as demand for PSMA-PET imaging in the United States continues to grow. This technol...

Read More
news image

Business Insights, PRACTICE MANAGEMENT

TELIX ANNOUNCES EXECUTIVE LEADERSHIP APPOINTMENTS

Telix Pharmaceuticals Limited | December 05, 2022

Telix Pharmaceuticals Limited announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession planning. Richard Valeix promoted to Group Chief Commercial Officer Richard Valeix, who has been in the role of Chief Executive Officer of Telix's Europe Middle East and Africa operations since joining Telix in May 2021, has been appointed to the newly created role of Group Chief Com...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us